ℹ️
🇬🇧
Search
Search for publications relevant for "Cardiovascular safety"
Cardiovascular safety
Publication
Class
Person
Publication
Programmes
publication
Cardiovascular safety of indakaterol in the treatment of COPD
2013 |
Third Faculty of Medicine
publication
Cardiovascular safety of liraglutide and semaglutide. Clinical comments to the discussed trials LEADER and SUSTAIN 6
2016 |
Second Faculty of Medicine
publication
Cardiovascular safety of coxibs.
2005 |
First Faculty of Medicine
publication
The study ORIGIN: Insulin glargine has become the reference basal analogue with proven cardiovascular safety
2013 |
Second Faculty of Medicine
publication
Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity
2021 |
First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
publication
Cardiovascular safety of testosterone replacement therapy
2023 |
Third Faculty of Medicine
publication
Changes of serum levels of hs-CRP and PAI-1 as markers of cardiovascular safety of hormone replacement therapy
Publication without faculty affiliation
publication
Cardiovascular safety of tocilizumab therapy: results of the ENTRACTE Clinical Trial
2018 |
First Faculty of Medicine
publication
New approaches to the treatment of type 2 diabetes mellitus
2017 |
First Faculty of Medicine
publication
London calling ... Impressions and findings from the annual congress of the European Society of Cardiology meeting on the 29th 8 to 2 9th 2015
2015 |
First Faculty of Medicine
publication
Vildagliptin nezvyšuje kardiovaskulární riziko diabetiků 2. typu
2018 |
Second Faculty of Medicine
publication
Komentář ke studii (Kardiovaskulární bezpečnost vildagliptinu u pacientů s diabetes mellitus 2. typu)
2017 |
First Faculty of Medicine
publication
Antidiabetic drugs and nephroprotection
2018 |
First Faculty of Medicine
publication
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY (R) study
2022 |
First Faculty of Medicine
publication
Antidiabetics and cardiovascular risk
2018 |
First Faculty of Medicine
publication
CVD_REAL: The Real Benefit of Gliglozins for the Treatment of Type 2 Diabetes in Common Clinical Practice
2018 |
Faculty of Medicine in Hradec Králové
publication
What news brought last year on oral antidiabetic drugs?
2016 |
First Faculty of Medicine, Third Faculty of Medicine
publication
Treatment of heart failure in diabetic patients
2014 |
First Faculty of Medicine
publication
Insulin glargine: a proven basal insulin analogue
2014 |
Second Faculty of Medicine
publication
Current role of gliptins in diabetes management
2022 |
Publication without faculty affiliation
publication
The benefit of gliptin therapy in elderly diabetics
2022 |
Publication without faculty affiliation
publication
The position of SGLT2 inhibitors in current medicine
2020 |
First Faculty of Medicine
publication
Why gerontodiabetology?
2021 |
Second Faculty of Medicine
publication
The position of SGLT2 inhibitors in current medical practice - update 2022
2022 |
First Faculty of Medicine
publication
What are the likely effects of new large studies from 2015 on the therapy type-2 diabetes?
2016 |
Second Faculty of Medicine
publication
Alogliptin and the fixed combination in the treatment of type 2 diabtes
2014 |
First Faculty of Medicine
publication
What's new in endocrinology?
2023 |
First Faculty of Medicine
publication
SGLT2 inhibitors in T2D and associated comorbidities differentiating within the class
2019 |
First Faculty of Medicine
publication
Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide
2015 |
First Faculty of Medicine
publication
Treatment of diabetes and cardiovascular risk: the end of a dogma in the treatment of type 2 diabetes
2016 |
First Faculty of Medicine